Fig 1.
a. MTN-030/IPM 041 Study Flow Diagram. MTN-030/IPM 041 Study Flow Diagram. b. MTN-044/IPM 053/CCN019 Study Flow Diagram. MTN-044/IPM 053/CCN019 Study Flow Diagram.
Table 1.
Demographics of evaluable participants.
Fig 2.
Concentration-time profiles for DPV and LNG in plasma and cervicovaginal fluid.
Median Dapivirine (DPV) and Levonorgestrel (LNG) concentrations in (A) blood plasma (pg/ml) and (B) cervicovaginal fluid (ng/mg). MTN-030/IPM 041 study data are represented by pink squares and labeled as ‘14-day’ in the legend. MTN-044/IPM 053/CCN019 study data are represented by blue (DPV) and green (LNG) circles and labeled as ‘90-day continuous’ (solid circles with solid connecting lines) and ‘90-day cyclic’ (open circles with dashed connecting lines) in the legend. Given the sparse sampling protocol not designed to evaluate the pharmacokinetics of return to steady-state drug concentrations following reinsertion of rings in cyclic users after days 30 and 60, double slash symbols to represent line breaks were drawn on the connecting lines of the curves between sampling on days 30 and 44 in the cyclic group. Arrows depict timing of ring removals for each group.
Table 2.
Median DPV and LNG concentrations in plasma, cervicovaginal fluid (CVF), and cervical tissue.
Table 3.
PK Parameters for DPV and LNG concentrations in plasma and cervicovaginal fluid (CVF).
Table 4.
Bleeding experiences with continuous compared to cyclic dapivirine/levonorgestrel vaginal ring use.